Navigation Links
AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay
Date:10/26/2010

VISTA, Calif., Oct. 26 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay.  The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.  

"We are very excited to receive FDA clearance for our 2C19 test" said Fareed Kureshy, President and CEO of AutoGenomics. "The necessity of this genetic test has been implicated in literature now for several years.  The FDA has now provided clinicians with a tool in determining medical strategies for therapeutics that are metabolized by the CYP 450 2C19 gene test specifically * 2, *3, *17. This is an important milestone in the era of personalized medicine. Several of our customers are awaiting such clearance to implement testing in their practice." He further said, "we continue to expand our portfolio of FDA cleared products." "The INFINITI® CYP 450 2C19 test is unique in evaluating *17 which can help clinicians identify ultra metabolizers" said Robert Cole, MD., Chief Medical Officer at AutoGenomics

The INFINITI® System features a broad menu of 42 applications, with 5 FDA cleared products and 16 CE marked products.

About AutoGenomics

AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com


'/>"/>
SOURCE AutoGenomics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
2. AutoGenomics New RVP Assay Addresses Current Challenge to Detect Flu A - Swine H1N1
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
5. UCLA engineering receives $6M to construct new state-of-the-art building
6. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
7. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
8. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
9. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq ... applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed ... the global industry association connecting the electronics manufacturing supply chain. The mission of ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):